{"denoms":[{"counts":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"16"}],"units":"Participants"}],"groups":[{"description":"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -3 and intermediate-dose melphalan IV over 15-20 minutes on day -2. Patients also undergo low-dose TBI on day 0.\n\nTRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.\n\nIMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 80 with taper to day 180 (related donors) or on days -3 to 100 with taper to day 180 (unrelated donors). Patients also receive mycophenolate mofetil PO BID on days 0-27 (related donors) or TID on days 0-40 with taper to day 96 (unrelated donors).\n\nfludarabine phosphate: Given IV melphalan: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given PO\n\nnonmyeloablative allogeneic hematopoietic stem cell transplantation: Undergo reduced-intensity allogeneic PBSCT\n\nperipheral blood stem cell transplantation: Undergo reduced-intensity allogeneic PBSCT\n\nlaboratory biomarker analysis: Correlative s","id":"BG000","title":"Related Donor"},{"description":"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -3 and intermediate-dose melphalan IV over 15-20 minutes on day -2. Patients also undergo low-dose TBI on day 0.\n\nTRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.\n\nIMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 80 with taper to day 180 (related donors) or on days -3 to 100 with taper to day 180 (unrelated donors). Patients also receive mycophenolate mofetil PO BID on days 0-27 (related donors) or TID on days 0-40 with taper to day 96 (unrelated donors).\n\nfludarabine phosphate: Given IV melphalan: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given PO\n\nnonmyeloablative allogeneic hematopoietic stem cell transplantation: Undergo reduced-intensity allogeneic PBSCT\n\nperipheral blood stem cell transplantation: Undergo reduced-intensity allogeneic PBSCT\n\nlaboratory biomarker analysis: Correlative s","id":"BG001","title":"Unrelated Donor"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"13"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"16"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"12"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"4"}]}],"title":"Italy"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}